The n e w e ng l a n d j o u r na l of m e dic i n e Original Article Trial of Lixisenatide in Early Parkinson’s Disease W.G. Meissner, P. Remy, C. Giordana, D. Maltête, P. Derkinderen, J.-L. Houéto, M. Anheim, I. Benatru, T. Boraud, C. Brefel‑Courbon, N....
More
The n e w e ng l a n d j o u r na l of m e dic i n e Original Article Trial of Lixisenatide in Early Parkinson’s Disease W.G. Meissner, P. Remy, C. Giordana, D. Maltête, P. Derkinderen, J.-L. Houéto, M. Anheim, I. Benatru, T. Boraud, C. Brefel‑Courbon, N. Carrière, H. Catala, O. Colin, J.-C. Corvol, P. Damier, E. Dellapina, D. Devos, S. Drapier, M. Fabbri, V. Ferrier, A. Foubert‑Samier, S. Frismand‑Kryloff, A. Georget, C. Germain, S. Grimaldi, C. Hardy, L. Hopes, P. Krystkowiak, B. Laurens, R. Lefaucheur, L.-L. Mariani, A. Marques, C. Marse, F. Ory‑Magne, V. Rigalleau, H. Salhi, A. Saubion, S.R.W. Stott, C. Thalamas, C. Thiriez, M. Tir, R.K. Wyse, A. Benard, and O. Rascol, for the LIXIPARK Study Group* A BS T R AC T BACKGROUND The authors’ full names, academic de- Lixisenatide, a glucagon-like peptide-1 receptor agonist used for the treatment of dia- grees, and affiliations are listed in the betes, has shown neuroprotective properties in a mouse model of Parkinson’s disease. Appendix
Less
